Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology Read more
Lilly’s Zepbound (tirzepatide) superior to Wegovy (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% Read more
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics Read more
Maze Therapeutics Announces Oversubscribed $115 Million Financing to Support Advancement of Clinical-Stage Programs and Future Pipeline Read more
Novartis bolsters Neuroscience pipeline with in-licensing of PTC518 for Huntington’s disease Read more
Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA (guselkumab) Read more
Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ, to the U.S. FDA Read more